One Dose Of Experimental Stem Cells And She Hasn't Needed Insulin Since.
Amanda Smith is a 36-year-old nurse and mother from London, Ontario, who was diagnosed with Type 1 diabetes at 25 and spent the years that followed managing everything that comes with it: the constant monitoring, the insulin injections, the mental math that runs in the background of every meal, every workout, every ordinary moment of life when your body can no longer do what a pancreas is supposed to do on its own. A little over two years ago, she received a single dose of laboratory-grown stem cells as part of a clinical trial, and on August 1 of that year she took her last insulin injection. She has not needed one since. The therapy is called zimislecel and was developed by Vertex Pharmaceuticals, working with research teams at the University Health Network in Toronto, and it works by infusing specially manufactured cells derived from embryonic stem cells directly into the liver, where they take hold within seconds and transform over the following four to six months into a functioning array of hormone-producing cells that sense blood glucose and secrete insulin the way a healthy pancreas does.
The results of the study, published in the New England Journal of Medicine and presented at the American Diabetes Association's 85th Scientific Sessions in Chicago, showed that 10 of the 12 participants who received the treatment were completely free of insulin injections after one year, a success rate that immediately caught the attention of the global diabetes research community. There is a significant caveat: patients must take immunosuppressant medication for as long as the stem cells remain active, to prevent the immune system from attacking the transplanted cells the same way it attacked the original beta cells. But for those who qualify, the shift in daily experience is profound. Smith told CTV that she no longer carries insulin, no longer fears the swings, and described the experience of being part of the study simply as history. Vertex plans to submit the therapy for regulatory approval in 2026, and researchers say real-world access for qualifying patients could follow within a few years if approval proceeds as hoped. Type 1 diabetes affects approximately 8.75 million people worldwide, and for most of them the daily reality of the disease has never had an ending.
